Evidence map›Paper›PMID 38267891›Full record

ArticleBMC cancer2024

A software tool to support follow-up care in a French childhood cancer cohort: construction and feasibility.

Charlotte Demoor-Goldschmidt, Pascal Veillon, Maxime Esvan, Mathilde Leonard, Sophie Chauvet, Amandine Bertrand, Liana Carausu, Fanny Delehaye, Julien Lejeune, Jérémie Rouger and 16 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
8.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 15 institutions in 1 country.

Charlotte Demoor-GoldschmidtDepartment of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers, France. charlotte.demoorgoldschmidt@chu-angers.fr.
Pascal VeillonDepartment of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers, France.
Maxime EsvanDepartment of Biostatitics, University Hospital of Rennes, Rennes, France.
Mathilde LeonardDepartment of Biostatitics, University Hospital of Rennes, Rennes, France.
Sophie ChauvetDepartment of Oncohematopediatrics, University Hospital of Nantes, Nantes, France.
Amandine BertrandDepartment of Oncohematopediatrics, IHope, Lyon, France.
Liana CarausuDepartment of Oncohematopediatrics, University Hospital of Brest, Brest, France.
Fanny DelehayeDepartment of Oncohematopediatrics, University Hospital of Caen, Caen, France.
Julien LejeuneDepartment of Oncohematopediatrics, University Hospital of Tours, Tours, France.
Jérémie RougerDepartment of Oncohematopediatrics, University Hospital of Caen, Caen, France.
Pascale SchneiderDepartment of Oncohematopediatrics, University Hospital of Rouen, Rouen, France.
Caroline ThomasDepartment of Oncohematopediatrics, University Hospital of Nantes, Nantes, France.
Frédéric MillotDepartment of Oncohematopediatrics, University Hospital of Poitiers, Poitiers, France.
Line ClaudeDepartment of Radiotherapy, Centre Leon Berard, Lyon, France.
Julie LeseurDepartment of Radiotherapy, Centre Eugène Marquis, Rennes, France.
Fernand MissohouDepartment of Radiotherapy, Centre François Baclesse, University of Caen, Caen, France.
Stéphane SupiotDepartment of Radiotherapy, Institut de Cancérologie de L'Ouest, Nantes, France.
Nathalie BihannicDepartment of Oncohematopediatrics, University Hospital of Brest, Brest, France.
Isabelle DebroiseAssociation Les Aguerris, Paris, France.
Carole JeanneaudDepartment of Oncohematopediatrics, University Hospital of Tours, Tours, France.
Esther LebretonDepartment of Oncohematopediatrics, University Hospital of Caen, Caen, France.
Marianne RoumyDepartment of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers, France.
Les AguerrisAssociation Les Aguerris, Paris, France.
Jean-Marie ChrétienData Science Department, Clinical and Innovation Direction, CHU Angers, Angers, France.
Virginie GandemerDepartment of Oncohematopediatrics, University Hospital of Rennes, Rennes, France.
Isabelle PellierDepartment of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers, France.
Université d'Angers · FRUniversité de Caen Normandie · FRCentre Hospitalier Régional Universitaire de Brest · FRCentre Hospitalier Universitaire de Rennes · FRNantes Université · FRCentre Eugène Marquis · FRCentre Hospitalier Universitaire d'Angers · FRCentre Hospitalier Universitaire de Tours · FRCentre Léon Bérard · FRInstitut de Cancérologie de l'Ouest · FRInstitut d’Hématologie et d’Oncologie Pédiatrique · FRUniversité de Poitiers · FRUniversité de Rennes · FRUniversité de Rouen Normandie · FRUniversité de Tours · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment summaries and a personalized survivorship care plans based on internationally approved, organ-specific follow-up care recommendations are essential in preserving the health and quality of life for cancer survivors. Cohorts made up of survivors of childhood cancer have made significant contributions to the understanding of early mortality, somatic late complications, and psychosocial outcomes among former patients. New treatment protocols are needed to enhance survival and reduce the potential risk and severity of late effects, and working with treatment databases is crucial in doing so. CONSTRUCTION AND CONTENT: In the GOCE (Grand Ouest Cancer de l'Enfant [Western Region Childhood Cancer]) network, in a participative approach, we developed the LOG-after medical tool, on which health data are registered and can be extracted for analysis. Its name emphasizes the tool's goal, referring to 'logiciel' (the French word for software) that focuses on the period "after" the acute phase. This tool is hosted on a certified health data server. Several interfaces have been developed that can be used depending on the user's profile. Here we present this innovative co-constructed tool that takes national aspects into account, including the results of the feasibility/satisfaction study and its perspective. UTILITY AND DISCUSSION: The database contains data relating to 2558 patients, with samples from 1702 of these (66.54%) being held in a tumor bank. The average year in which treatment started was 2015 (ranging from December 1967 to November 2022: 118 patients were treated before 2012 and registered retrospectively when seen in long-term follow-up consultations or for another cancer since November 2021). A short questionnaire was distributed to healthcare professionals using the tool (physicians and research associates or technicians, n = 14), of whom 11 answered and were all satisfied. Access to the patient interface is currently open to 124 former patients. This was initially offered to 30 former patients who were over 15 years old, affected by the disease within the last 5 years, and had agreed to test it. Their opinions were collected by their doctor by e-mail, telephone, or during a consultation in an open-ended question and a non-directive interview. All patients were satisfied with the tool, with interest in testing it in the long term. Some former patients found that the tool provided them with some ease of mind; one, for instance, commented: "I feel lighter. I allow myself to forget. I know I will get a notification when the time comes."

conclusionsFreely available to all users, LOG-after: (1) provides help with determining personalized survivorship care plans for follow-up; (2) builds links with general practitioners; (3) empowers the patient; and (4) enables health data to be exported for analysis. Database URL for presentation: https://youtu.be/2Ga64iausJE.

Indexed as

AftercareNeoplasmsAdolescentChildFeasibility StudiesHumansQuality of LifeRetrospective StudiesSoftwareAdolescent cancerChemotherapyChildhood cancerDatabaseMedical toolPersonalized survivorship care planRadiotherapySurvivorship

Identifiers

PMID38267891
PMCPMC10809785
OpenAlexW4391187982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.